{"nctId":"NCT00136318","briefTitle":"Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients","startDateStruct":{"date":"2004-01"},"conditions":["Depression"],"count":208,"armGroups":[{"label":"Escitalopram","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Escitalopram","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]}],"interventions":[{"name":"Escitalopram","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Peginterferon alfa-2a","otherNames":["PEG-IFN alfa-2a","Pegasys"]},{"name":"Ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic hepatitis C infection defined as positive anti-HCV antibodies and serum HCV-RNA \\>1000 IU/ml, naive to antiviral treatment\n* age \\>18 years\n\nExclusion Criteria:\n\n* Antidepressive treatment within the last 3 years\n* Psychiatric diseases including major depressive disorders in past medical history\n* Active substance abuse during the last 12 months\n* Pregnancy, lactation, wish to become pregnant\n* Hepatitis B (HBV)/HIV-coinfection\n* Decompensated liver disease, hepatocellular carcinoma, history of bleeding esophageal varices\n* Neutropenia (\\<1500/ul), thrombocytopenia (\\<70/nl), anemia (\\<12g/dl in females, \\<13g/dl in males)\n* History of autoimmune disease\n* History of organ transplantation, concomitant liver disease, severe cardiopulmonary disease, hemolytic anemia, malignant disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher","description":"Clinically relevant depression (MADRS score of 13 or higher) during antiviral treatment presented as \"percentage of participants\" with \"MADRS scores \\> 13\" (entire time period: from starting study medication until end of antiviral treatment = 48 weeks in patients with genotype 1 or 4 and 24 weeks for patients with genotype 2 or 3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)","description":"Number of patients who did not develop at any time of antiviral treatment (up to 48 weeks) a MADRS score of 13 or more as a sign of clinically relevant depression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Severe Depression Defined as a MADRS Score of 25 or Higher","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (HRQOL) Measured by the Short Form 36 (SF-36)","description":null,"classes":[]},{"type":"SECONDARY","title":"Sustained Virologic Response","description":"(negative Polymerase Chain Reaction (PCR) 6 months after the end of antiviral treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability","description":null,"classes":[]},{"type":"SECONDARY","title":"Safety","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":90},"commonTop":["Fatigue","Dizziness","Anemia"]}}}